Neuropathy

Current Location

51 Neuropathy Trials Near You

Power is an online platform that helps thousands of Neuropathy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
The purpose of this study is to assess the effects of Transcranial Direct Current Stimulation (tDCS) in combination with Transcranial ultrasound (TUS) for the treatment of pain and functional limitations in subjects with Diabetic Neuropathic Pain.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:40 - 80

60 Participants Needed

This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety and tolerability, efficacy, immunogenicity, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ARGX-117 Intravenously (IV) in adults with Multifocal Motor Neuropathy (MMN). The trial will include a double-blinded rollover treatment period (DTP), an open-label treatment period (OTP), and a safety follow-up period.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

51 Participants Needed

This trial aims to help people who have lost a leg by using small devices that send electrical signals to nerves and record muscle activity. These signals help the brain feel sensations from the missing limb, and the muscle data helps control a robotic leg more naturally.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

15 Participants Needed

This trial is testing a medication called patisiran. It aims to help people with a heart condition caused by abnormal protein buildup. The medication works by lowering the levels of these harmful proteins in the body. Patisiran has been shown to significantly reduce symptoms and improve quality of life in patients.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

360 Participants Needed

This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

655 Participants Needed

This single-cohort, prospective case series is designed to evaluate and characterize the use of Axoguard HA+ Nerve Protector™ to protect the ulnar nerve in a first revision cubital tunnel decompression procedure. Data on the primary cubital tunnel syndrome decompression, first revision decompression utilizing Axoguard HA+ Nerve Protector, participant-reported pain, motor and sensory functional outcomes, quality of life (QoL) outcomes, and recurrence/revision will be collected. This case series will help to establish the ability of Axoguard HA+ Nerve Protector to provide clinical benefits for patients undergoing a first revision cubital tunnel decompression procedure.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

20 Participants Needed

This trial is testing a new drug called LY3556050 to see if it can help reduce nerve pain in people with diabetes. The study will last several months and will compare the effects of LY3556050 to another treatment. The goal is to determine if LY3556050 is safe and effective for treating diabetic nerve pain.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

410 Participants Needed

This is a double-blind randomised controlled trial (RCT) which compares the effectiveness of three surgical techniques for alleviating residual limb pain (RLP), neuroma pain and phantom limb pain (PLP). The three surgical treatments are Targeted Muscles Reinnervation (TMR), Regenerative Peripheral Nerve Interface (RPNI), and an active control (neuroma excision and muscle burying). Patients will be follow-up for 4 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

110 Participants Needed

To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease. The trial period will comprise a Screening period (up to 35 Days), randomization and a 4-day treatment period, followed by a 12-week follow up period (12 weeks total after initial treatment), and an End-of-Trial/Follow-up visit which will occur at Week 13. This is a study to research the effects of the study drug on neuropathic pain compared placebo.

Trial Details

Trial Status:Recruiting
Age:21+

222 Participants Needed

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy. The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC). This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks. Participants will: * Undergo a quantitative sensory testing (QST) exam. * Provide a blood sample. * Complete questionnaires on the computer. * Take the study drug as instructed.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

190 Participants Needed

Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting about 50% of patients with diabetes and leading to severe morbidity, poor quality of life, high mortality, and high health care costs. Due to the complex structure and anatomy of the peripheral nervous system, DPN presents with a very broad spectrum of clinical symptoms and deficits, including severe pain, sensory deficits, foot ulcers and amputations. Presently there is no treatment for DPN and even with good blood glucose control DPN develops especially in patients with type 2 diabetes. There is a need to identify effective interventions for DPN. Preclinical studies have provided evidence that the combination of fish oil and salsalate is an effective treatment of DPN. The human subject study to be performed will examine the effect of fish oil with and without salsalate on the blood lipid profile and circulating metabolites of omega-3 polyunsaturated fatty acids (PUFA). Fish oil is an excellent source for the nutrition dependent omega-3 PUFA, primarily eicosapentaenoic acid (EPA; 20:5) and docosahexaenoic acid (DHA; 22:6). These fatty acids are the source of anti-inflammatory metabolites known as resolvin, neuroprotectin and maresin. Preclinical studies have also demonstrated that the metabolites of EPA and DHA are neuroprotective. Furthermore, when fish oil is combined with salsalate the production of these metabolites is increased in vivo. Thus, the investigators hypothesize that fish oil and salsalate will be an effective therapy of DPN. However, prior to doing a formal study of the effect of fish oil + salsalate on DPN there is a need to learn more about what concentration combination will provide the most efficacious effect on the omega-3 index (defined as the sum of EPA and DHA, as a percentage of total fatty acids in red blood cells) and that will safely increase the production of the anti-inflammatory metabolites. These studies will be performed at two sites the University of Iowa (Dr. Yorek) and University of Michigan (Dr. Pop-Busui) by treating human subjects with type 2 diabetes and DPN with either 2g or 4g of fish oil per day (capsules) for 4 months and then adding salsalate 1.5 g or 3g per day (tablets) to the fish oil treatments for an additional 2 months. At baseline and after treatment with fish oil alone and after treatment with the combination of fish oil and salsalate the omega-3 index and levels of circulating omega-3 PUFA metabolites will be determined as primary endpoints. Secondary endpoints will include determination of circulatory inflammatory markers and non-invasive measurements for DPN. The risks to subjects are minimal and are very reasonable in relation to the importance of the knowledge to be gained.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

100 Participants Needed

This trial will test a treatment called Panzyga on patients with small fiber neuropathy (SFN). SFN patients often suffer from undiagnosed pain, and current treatments have many side effects. Panzyga may help by reducing inflammation and improving nerve function, potentially reducing pain and increasing nerve density in the skin. Panzyga has been shown to be effective in treating various autoimmune neurological disorders and has potential benefits for managing neuropathic pain.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

20 Participants Needed

This trial involves PXT3003, a mix of three low-dose drugs, aimed at patients with CMT1A. The drug combination aims to improve nerve function and reduce disability. Earlier research has shown preliminary evidence of efficacy for PXT3003 in treating CMT1A.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:17 - 67

187 Participants Needed

MBSR for Chronic Pain

Ann Arbor, Michigan
The overall objective of this study is to better understand how Mindfulness-based Stress Reduction (MBSR) is the most helpful in terms of management of chronic pain symptoms. The studies hypothesis is that an Interventional Response Phenotyping study (light phenotyping) can identify individuals with different underlying mechanisms for their pain who thus respond differentially to evidence-based interventions for chronic pain disorders.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

300 Participants Needed

Halneuron for Neuropathy

Farmington, Michigan
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

200 Participants Needed

The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity of CIPN in the hands. The investigators hypothesize that daily vibration therapy can reduce the severity of patient's CIPN in their hands and improve CIPN-related quality of life. The hope is that results from this study will provide early data on the feasibility, efficacy, and most importantly, safety, of daily 3-minute hand-held vibration therapy needed to justify future clinical trials examining vibration therapy as a potential option for treating CIPN in the future.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

16 Participants Needed

This trial is testing the safety of Eplontersen, a medication given regularly, in patients with a genetic condition that causes nerve damage. The treatment works by lowering harmful protein levels to reduce nerve damage.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

151 Participants Needed

This trial tests a skin cream called WST-057 on patients receiving chemotherapy with Carboplatin and Paclitaxel. The cream is applied to the skin to help manage side effects from the chemotherapy. Carboplatin and Paclitaxel are frequently used together in treatments for various cancers, including gynecological malignancies.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

60 Participants Needed

The investigators aim to determine the effect of cryotherapy wraps plus compression therapy (henceforth referred to as cryocompression) versus cryotherapy wraps alone on the incidence and degree of chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer using a noninferiority design. The investigators also aim to determine the effect of cryocompression versus cryotherapy on patient tolerability and patient and staff satisfaction.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Sex:Female

190 Participants Needed

A novel temporary peripheral nerve stimulation system that delivers electrical stimulation therapy in a cubital tunnel release model will be evaluated for feasibility.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

26 Participants Needed

Why Other Patients Applied

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78
This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and is caused by chemotherapy. PEA may be useful against bothersome nerve symptoms.

Trial Details

Trial Status:Active Not Recruiting

88 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Neuropathy clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Neuropathy clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Neuropathy trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Neuropathy is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Neuropathy medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Neuropathy clinical trials?

Most recently, we added Gene Therapy for Charcot-Marie-Tooth Disease, Pregabalin + Duloxetine for Peripheral Neuropathy and Halneuron for Neuropathy to the Power online platform.

Does anything really work for neuropathy?

Yes—real results come from tackling neuropathy on two fronts. First, fix the underlying cause whenever possible (tighten blood-sugar control, replace low B-12, adjust thyroid levels, stop a toxic medication, or use immune treatment for disorders like CIDP) because this can slow or even reverse nerve damage. Second, control the discomfort with proven options—prescription pills such as duloxetine or pregabalin/gabapentin, high-dose capsaicin or lidocaine skin patches, plus regular aerobic exercise and physical therapy—which can markedly cut burning, tingling or numbness while the root problem is being addressed.

What triggers neuropathy flare-ups?

A neuropathy “flare” usually happens when already-injured nerves face extra stress. The most common stressors fall into four buckets: 1) metabolic swings such as high or rapidly changing blood sugar or low vitamin B12, 2) lifestyle chemicals like alcohol or smoking, 3) mechanical or environmental insults—tight shoes, prolonged pressure, cold or heat, vibrations—or 4) medicines and illnesses that irritate nerves (certain chemotherapies, infections, thyroid or kidney problems). Tracking your symptoms alongside these factors (e.g., glucose readings, alcohol intake, recent medications, exposures) can help you and your doctor pinpoint personal triggers and plan ways to avoid them.

Is foot neuropathy progressive?

Most kinds of foot neuropathy do tend to worsen over time, especially when the underlying cause—such as poorly controlled diabetes, ongoing alcohol use, or certain chemotherapy drugs—continues to injure the nerves. Progression is not inevitable, though; correcting a vitamin-B12 shortage, improving blood-sugar levels, changing a medication, or simply protecting the feet can slow, stop, and sometimes partly reverse the damage. The takeaway: work with your clinician to pin down the cause early and tackle those risk factors so the condition doesn’t silently advance.

Are eggs bad for neuropathy?

For most people with neuropathy, an egg or two a few times a week is safe and can even help by providing vitamin B12 and choline that nerves need; the exception is if you have an egg allergy or your doctor has asked you to limit cholesterol. Focus on a balanced plate—plenty of vegetables, whole grains, and lean proteins—while monitoring blood sugar, weight, and how your body feels after different foods; if eggs don’t trigger symptoms and your lab numbers stay on target, they aren’t “bad” for your neuropathy.

What is often mistaken for neuropathy?

Several other problems can create numbness, tingling or burning, so neuropathy is often confused with a pinched nerve in the spine (radiculopathy), poor circulation to the legs and feet (peripheral artery disease), widespread pain disorders like fibromyalgia, vitamin B-12 deficiency, restless-leg syndrome, or brain/spinal-cord diseases such as multiple sclerosis. Notice whether symptoms stay in one limb, change with posture or walking, improve when you move, or come with fatigue, vision or wound-healing issues—those patterns can hint at a cause other than nerve damage. Because each condition has different treatments, any persistent or worsening sensation changes should be evaluated by a healthcare professional.

Can nerves regenerate from neuropathy?

Peripheral nerves can regrow, but they do so slowly—about a millimetre a day—so recovery takes months and is most successful when the underlying cause (like diabetes, vitamin B-12 deficiency, or pressure on a nerve) is corrected early. Full return of feeling or strength isn’t guaranteed, yet good blood-sugar control, stopping toxins (alcohol, certain drugs), proper vitamins, and guided exercise greatly improve the odds; nerves in the brain or spinal cord, however, rarely regenerate. In short, ask your doctor to hunt for—and treat—the cause, protect the numb area while healing occurs, and be patient with the gradual progress.

What vitamin is used for neuropathy?

The best-studied “nerve vitamins” are B-vitamins—especially B12 (about 1 mg daily or by injection for deficiency) and the B1 derivative benfotiamine (150–300 mg twice daily)—which small clinical trials show can improve nerve pain and conduction in diabetic or alcoholic neuropathy; vitamin B6 helps only if levels are low and should stay below 100 mg a day to avoid toxicity. Emerging research suggests that correcting low vitamin D (e.g., 1000–2000 IU daily, or higher short courses under medical supervision) may ease diabetic nerve pain, whereas other vitamins or minerals have little proof. Because dosing and causes of neuropathy vary, ask your doctor to measure B12 and vitamin D levels and guide any supplementation.

Is there a walking device for neuropathy?

Yes. Options range from sensory-substitution wearables like Walkasins that vibrate above the ankle to restore lost foot feedback, to functional-electrical-stimulation braces for foot-drop and standard aids such as canes or trekking poles; each targets different neuropathy-related walking problems. A physical therapist or neurologist can test your sensation and balance and let you trial the device type most likely to improve your safety and confidence.

How to stop neuropathy from progressing?

Nerves keep getting damaged only if the thing that is hurting them stays active, so the first step is to have a doctor pin down the exact cause—-for example high blood sugar, low vitamin B-12, alcohol, a pinched nerve, or an immune condition—and treat or remove it right away. At the same time, you can give the nerves their best chance to stabilise by exercising gently every day, eating a nutrient-rich diet, stopping smoking and excess alcohol, and checking your feet and skin daily for injuries you might not feel.

Do magnets help neuropathy?

Current research on magnets for neuropathy is sparse and low-quality; small studies sometimes show pain relief, but just as many find no difference, and no professional guidelines endorse magnetic devices for neuropathic pain. Magnets appear harmless for most people (keep them away from pacemakers), but because evidence of benefit is weak, they should be viewed—at best—as an optional add-on rather than a substitute for proven treatments like good glucose control, exercise, medications (e.g., duloxetine, gabapentin), and foot care.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security